Tirzepatide markedly lowers mortality, hospitalizations, and MACE in T2DM with heart failure vs. DPP-4is.
Background
Patients with type 2 diabetes mellitus (T2DM) frequently develop heart failure (HF), a condition that significantly increases morbidity and mortality. While dipeptidyl peptidase-4 inhibitors (DPP-4is) are commonly prescribed for glycemic control in this population, their cardiovascular benefits, particularly in HF, are limited. Emerging evidence suggests that glucagon-like peptide-1 receptor agonists (GLP-1 RAs) may offer superior cardiovascular outcomes. This study addresses the gap by directly comparing the effectiveness of tirzepatide, a dual GLP-1R/GIPR agonist, against DPP-4is in this high-risk patient group.
Study Design
This comparative effectiveness study included adults with T2DM and HF treated between 2022 and 2025. Patients were divided into Cohort A, receiving tirzepatide, and Cohort B, receiving DPP-4is. To ensure comparability, propensity score matching was meticulously performed across a wide array of demographic, clinical, medication, and laboratory covariates. After matching, 8,956 patients were included in each group. Prespecified subgroup analyses were conducted for HF with reduced ejection fraction (HFrEF) and HF with non-reduced ejection fraction (HFnonrEF). Primary outcomes assessed included all-cause mortality, hospitalization, HF exacerbation, and major adverse cardiovascular events (MACE).
Results
Treatment with tirzepatide demonstrated significantly superior outcomes compared to DPP-4 inhibitors across all measured endpoints. The most striking finding was a substantial reduction in all-cause mortality.
Tirzepatide therapy was associated with a lower hazard of all-cause mortality (HR 0.32, 95% CI 0.25-0.42), indicating a 68% reduction in risk.
Furthermore, patients on tirzepatide experienced a lower hazard of hospitalizations (HR 0.53, 95% CI 0.48-0.57), representing a 47% reduction. HF exacerbation rates were also markedly lower with tirzepatide (HR 0.37, 95% CI 0.33-0.42), a 63% reduction. Finally, MACE incidence was significantly reduced by 21% (HR 0.79, 95% CI 0.73-0.84) in the tirzepatide group. Subgroup analyses for both HFrEF and HFnonrEF populations consistently showed similar beneficial trends, reinforcing the broad applicability of these findings across different HF phenotypes.
Key Findings
- Tirzepatide reduced all-cause mortality by 68% (HR 0.32, 95% CI 0.25-0.42) compared to DPP-4 inhibitors.
- Hospitalizations were 47% lower with tirzepatide (HR 0.53, 95% CI 0.48-0.57).
- Tirzepatide cut heart failure exacerbations by 63% (HR 0.37, 95% CI 0.33-0.42).
- Major adverse cardiovascular events (MACE) decreased by 21% (HR 0.79, 95% CI 0.73-0.84) with tirzepatide.
- Benefits were consistent across both
HFrEFandHFnonrEFsubgroups.
Why It Matters
This study provides compelling real-world evidence that tirzepatide offers substantial cardiovascular and mortality benefits for patients with T2DM and HF, significantly outperforming DPP-4 inhibitors. For clinicians, this suggests a strong rationale to prioritize tirzepatide over DPP-4is in this high-risk population, potentially shifting standard-of-care protocols. The practical takeaway is that tirzepatide should be considered a front-line therapy for T2DM patients with co-existing heart failure, not just for glycemic control but for its profound cardioprotective effects. While this is an observational study, the large sample size and robust propensity score matching lend significant weight to its conclusions, moving us closer to definitive clinical guidelines. This data supports integrating dual GLP-1R/GIPR agonism into comprehensive management strategies for T2DM with HF.
tirzepatide
type 2 diabetes
heart failure
dpp-4 inhibitors
cardiovascular
mortality